{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:21Z","timestamp":1791868941603,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00108-019-0575-x","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T16:03:26Z","timestamp":1552493006000},"page":"478-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rapid-progressive Glomerulonephritis","Rapid progressive glomerulonephritis"],"prefix":"10.1007","volume":"60","author":[{"given":"Marion","family":"Haubitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"575_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2012","unstructured":"Jennette JC, Falk RJ, Bacon PA et\u00a0al (2012) Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"575_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy327","author":"M Segelmark","year":"2018","unstructured":"Segelmark M, Hellmark T (2018) Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfy327","journal-title":"Nephrol. Dial. Transplant."},{"key":"575_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.2169\/internalmedicine.43.660","volume":"43","author":"M Haubitz","year":"2004","unstructured":"Haubitz M, Woywodt A (2004) Circulating endothelial cells and vasculitis. Intern Med 43:660\u2013667","journal-title":"Intern Med"},{"key":"575_CR4","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2215\/CJN.02500317","volume":"12","author":"J Jennette","year":"2017","unstructured":"Jennette J, Nachman PH (2017) ANCA glomerulonephritis and vasculitis. J\u00a0Am Soc Nephrol 12:1680\u20131691","journal-title":"J Am Soc Nephrol"},{"key":"575_CR5","doi-asserted-by":"crossref","first-page":"41764","DOI":"10.18632\/oncotarget.16986","volume":"8","author":"D Roccatello","year":"2017","unstructured":"Roccatello D, Sciascia S, Rossi D et al (2017) The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agens. Oncotarget 8:41764\u201341777","journal-title":"Oncotarget"},{"key":"575_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0043-106566","volume":"143","author":"M Haubitz","year":"2018","unstructured":"Haubitz M (2018) Nierenbeteiligung bei ANCA-assoziierten Vaskulitiden. Dtsch Med Wochenschr 143:79\u201388","journal-title":"Dtsch Med Wochenschr"},{"key":"575_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J\u00a0Am Soc Nephrol 21:1628\u20131636","journal-title":"J Am Soc Nephrol"},{"key":"575_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/CJN.04290417","volume":"13","author":"EE Daalen Van","year":"2018","unstructured":"Van Daalen EE, Jennette JC, McAdoo SP et al (2018) Predicting outcome in patients with anti-GMB glomerulonephritis. Clin J Am Soc Nephrol 13:63\u201372","journal-title":"Clin J Am Soc Nephrol."},{"key":"575_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","volume":"41","author":"M Haubitz","year":"1998","unstructured":"Haubitz M, Schellong S, G\u00f6bel U et al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with ANCA-associated vasculitis and renal involvement: a\u00a0prospective, randomized study. Arthritis Rheum 41:1835\u20131844","journal-title":"Arthritis Rheum"},{"key":"575_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot","year":"2009","unstructured":"Groot K, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a\u00a0randomized trial. Ann Intern Med 150:670\u2013678","journal-title":"Ann. Intern. Med."},{"key":"575_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfn430","volume":"24","author":"S Lovric","year":"2009","unstructured":"Lovric S, Erdbruegger U, Kuempers P et\u00a0al (2009) Rituximab as rescue therapy in ANCA associated vasculitis single centre experience with fifteen patients. Nephrol Dial Transplant 24:179\u2013185","journal-title":"Nephrol Dial Transplant"},{"key":"575_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N\u00a0Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"575_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"575_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","volume":"34","author":"SP McAdon","year":"2019","unstructured":"McAdon SP, Medjeral-Thomas N, Gopaluni S (2019) Long-term follow-up of a\u00a0combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34:63\u201373","journal-title":"Nephrol. Dial. Transplant."},{"key":"575_CR15","first-page":"146","volume":"30","author":"WM Szpirt","year":"2015","unstructured":"Szpirt WM (2015) Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis\u2014a\u00a025-year perspective. Nephrol Dial Transplant 30:146\u2013149","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"575_CR16","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"D Jayne","year":"2007","unstructured":"Jayne D, Gaskin G, Rasmussen NH et\u00a0al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180\u20132188","journal-title":"J Am Soc Nephrol"},{"key":"575_CR17","unstructured":"Walsh M, Merkel PA, Jayne D et al (2018) The effects of plasma exchange and reduced-dose glucocorticoids during remission\u2014induction for treatment of severe ANCA-associated vasculitis. J\u00a0Am Soc Nephrol 29: (59 (Abstract))"},{"key":"575_CR18","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Brachfeld AN, Harper L et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J\u00a0Am Soc Nephrol 28:2756\u20132767","journal-title":"J Am Soc Nephrol"},{"key":"575_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12882-018-1038-7","volume":"19","author":"M Heitz","year":"2018","unstructured":"Heitz M, Carron PL, Claarino G et al (2018) Use of rituximab as an induction therapy in antiglomerular basement-membrane disease. BMC Nephrol 19:241\u2013247","journal-title":"BMC Nephrol"},{"key":"575_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542\u2013548","journal-title":"Arthritis Rheum"},{"key":"575_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Marth A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in ANCA-associated vasculitis: a\u00a0meta-analysis. Arthritis Care Res 62:116\u20131173","journal-title":"Arthritis Care Res"},{"key":"575_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen NH, Andrassy K et\u00a0al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36\u201344","journal-title":"N Engl J Med"},{"key":"575_CR23","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76:1662\u20131668","journal-title":"Ann Rheum Dis"},{"key":"575_CR24","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371:1771\u20131780","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0575-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0575-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0575-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T10:44:34Z","timestamp":1606733074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0575-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0575-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"13 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Haubitz hat Vortragshonorare von der Firma Roche erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}